FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:1639-1641 May 24, 2001 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: In his editorial (Jan. 18 issue)¹ accompanying two studies^2,3 demonstrating the safety of discontinuing prophylaxis against Pneumocystis carinii pneumonia after an antiretroviral therapy–induced rise in the CD4 cell count, Girard writes that other independent risk factors for P. carinii pneumonia should be taken into account when one is making this decision. We present a case report that underscores the importance of this recommendation.

A 42-year-old man who was seropositive for the human immunodeficiency virus (HIV) was admitted to the hospital with shortness of breath, fever, and cough. Four years earlier, he had been treated successfully for non-Hodgkin's . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Atzori, C., Clerici, M., Trabattoni, D., Fantoni, G., Valerio, A., Tronconi, E., Cargnel, A. (2003). Assessment of immune reconstitution to Pneumocystis carinii in HIV-1 patients under different highly active antiretroviral therapy regimens. J Antimicrob Chemother 52: 276-281 [Abstract] [Full Text]